Literature DB >> 33946202

Biological Cloth Face Coverings-The Reduction of SARS-CoV-2 and Influenza (H1N1) Infectivity by Viruferrin™ Treatment.

Emily S Medina-Magües1, Anna Stedman2, Paul Hope2, Jorge E Osorio1,3.   

Abstract

In an attempt to create novel methods to reduce the transmission of SARS-CoV-2 and influenza viruses, fabric material was treated with Viruferrin™ and tested for its inactivating properties against the pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A viruses. Inactivating properties were evaluated by comparing Viruferrin-treated and cotton control fabric material with and without the application of saliva at various time points after virus exposure. A statistically significant (p < 0.0001) decrease in the number of infectious virus particles exposed to Viruferrin-treated fabric when compared with the cotton control for both SARS-CoV-2 and influenza A viruses was observed. For both SARS-CoV-2 and influenza A, Viruferrin-treated fabrics experienced a >99% virus reduction without saliva after five minutes of contact when compared to the positive control at time point 0. Furthermore, the reusability of the Viruferrin treated fabric was demonstrated by stability for up to 10 washes. The level of anti-viral (SARS-CoV-2) activity remained constant from 5 to 10 washes and demonstrated a significant difference (p < 0.0001) from the unwashed untreated material. Applications for this treated fabric are far reaching, as a biological face covering offers not only a unique 2-way protection but also is unlikely to cause onward touch transmission.

Entities:  

Keywords:  COVID-19; aerosols; droplet; face masks; personal protective equipment; personal protective material

Year:  2021        PMID: 33946202     DOI: 10.3390/ma14092327

Source DB:  PubMed          Journal:  Materials (Basel)        ISSN: 1996-1944            Impact factor:   3.623


  10 in total

1.  Improved docking of polypeptides with Glide.

Authors:  Ivan Tubert-Brohman; Woody Sherman; Matt Repasky; Thijs Beuming
Journal:  J Chem Inf Model       Date:  2013-07-10       Impact factor: 4.956

2.  Evaluation of Cloth Masks and Modified Procedure Masks as Personal Protective Equipment for the Public During the COVID-19 Pandemic.

Authors:  Phillip W Clapp; Emily E Sickbert-Bennett; James M Samet; Jon Berntsen; Kirby L Zeman; Deverick J Anderson; David J Weber; William D Bennett
Journal:  JAMA Intern Med       Date:  2021-04-01       Impact factor: 21.873

3.  Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.

Authors:  A Danielle Iuliano; Katherine M Roguski; Howard H Chang; David J Muscatello; Rakhee Palekar; Stefano Tempia; Cheryl Cohen; Jon Michael Gran; Dena Schanzer; Benjamin J Cowling; Peng Wu; Jan Kyncl; Li Wei Ang; Minah Park; Monika Redlberger-Fritz; Hongjie Yu; Laura Espenhain; Anand Krishnan; Gideon Emukule; Liselotte van Asten; Susana Pereira da Silva; Suchunya Aungkulanon; Udo Buchholz; Marc-Alain Widdowson; Joseph S Bresee
Journal:  Lancet       Date:  2017-12-14       Impact factor: 79.321

4.  Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks.

Authors:  Abhiteja Konda; Abhinav Prakash; Gregory A Moss; Michael Schmoldt; Gregory D Grant; Supratik Guha
Journal:  ACS Nano       Date:  2020-04-24       Impact factor: 15.881

Review 5.  A systematic review of asymptomatic infections with COVID-19.

Authors:  Zhiru Gao; Yinghui Xu; Chao Sun; Xu Wang; Ye Guo; Shi Qiu; Kewei Ma
Journal:  J Microbiol Immunol Infect       Date:  2020-05-15       Impact factor: 4.399

Review 6.  Manipulation of the Innate Immune Response by Varicella Zoster Virus.

Authors:  Chelsea Gerada; Tessa M Campbell; Jarrod J Kennedy; Brian P McSharry; Megan Steain; Barry Slobedman; Allison Abendroth
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

7.  6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.

Authors:  Chaolin Huang; Lixue Huang; Yeming Wang; Xia Li; Lili Ren; Xiaoying Gu; Liang Kang; Li Guo; Min Liu; Xing Zhou; Jianfeng Luo; Zhenghui Huang; Shengjin Tu; Yue Zhao; Li Chen; Decui Xu; Yanping Li; Caihong Li; Lu Peng; Yong Li; Wuxiang Xie; Dan Cui; Lianhan Shang; Guohui Fan; Jiuyang Xu; Geng Wang; Ying Wang; Jingchuan Zhong; Chen Wang; Jianwei Wang; Dingyu Zhang; Bin Cao
Journal:  Lancet       Date:  2021-01-08       Impact factor: 79.321

8.  Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study.

Authors:  Benjamin Rader; Laura F White; Michael R Burns; Jack Chen; Joseph Brilliant; Jon Cohen; Jeffrey Shaman; Larry Brilliant; Moritz U G Kraemer; Jared B Hawkins; Samuel V Scarpino; Christina M Astley; John S Brownstein
Journal:  Lancet Digit Health       Date:  2021-01-19

Review 9.  Lactoferrin as potential preventative and adjunct treatment for COVID-19.

Authors:  Raymond Chang; Tzi Bun Ng; Wei-Zen Sun
Journal:  Int J Antimicrob Agents       Date:  2020-07-30       Impact factor: 5.283

10.  European intensive care physicians' experience of infections due to antibiotic-resistant bacteria.

Authors:  Alain Lepape; Astrid Jean; Jan De Waele; Arnaud Friggeri; Anne Savey; Philippe Vanhems; Marie Paule Gustin; Dominique L Monnet; José Garnacho-Montero; Anke Kohlenberg
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-02       Impact factor: 4.887

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.